OAS1 Antibody
(Synonyms: OIAS, OAS1, 2'-5'-oligoadenylate synthase 1, (2-5')oligo(A) synthase 1, 2-5A synthase 1, E18/E16, p46/p42 OAS)OAS1 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to OAS1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in PBS (pH 7.4), containing 30% glycerol, and 0.01% sodium azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
|---|---|---|---|
| Dilution Ratio | 1:1000-2000 | 1:100-200 | 1:50-200 |
Product Details
OAS1 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to OAS1.
-
Host Rabbit
-
Clonality Polyclonal
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 40 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 41; 43; 46; 47 kDa
Purified recombinant protein of human OAS1
Endogenous
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH 7.4), containing 30% glycerol, and 0.01% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
OAS1 is an Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Catalyzes the formation of 2'-5'-oligoadenylates (2-5A) from polymerization of ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Involved in intercellular immune signaling that limits local spread of RNA virus infection and protects against tumorigenesis. Can generate high levels of 2',5'-oligoadenylates in transformed cells, targeting them to innate and adaptive immunesurveillance mechanisms. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L[1][2][3].
-
Subcellular Localization
Cytoplasm; Mitochondrion; Nucleus; Microsome; Endoplasmic reticulum; Secreted
-
Expression
Tissue_Specificity: Expressed in lungs.
Induction: By type I interferon (IFN) and viruses. -
Isoforms & Post-Translational Modification
OAS1 has 4 isoforms, P00973-1: amino acid length is 400, molecular weight is 46029 Da (predicted); P00973-2: amino acid length is 364, molecular weight is 41740 Da (predicted); P00973-3: amino acid length is 414, molecular weight is 47408 Da (predicted); P00973-4: amino acid length is 360, molecular weight is 41475 Da (predicted).
Prenylated at C-terminal. C-terminal prenylation is necessary to initiate a block to SARS-CoV-2 and is associated with protection from severe COVID-1. The prenylated form is targeted to perinuclear structures rich in viral dsRNA, whereas the non-prenylated form is diffusely localized and unable to initiate a detectable block to SARS-CoV-2 replication (Probable). C-terminal prenylation is also necessary to initiate a block to cardiovirus EMCV (Probable). -
Subunit
Monomer.
-
SwissProt ID
-
Synonyms
OIAS, OAS1, 2'-5'-oligoadenylate synthase 1, (2-5')oligo(A) synthase 1, 2-5A synthase 1, E18/E16, p46/p42 OAS
Documentation
[1]. Wickenhagen A, et al. A prenylated dsRNA sensor protects against severe COVID-19. Science. 2021 Oct 29;374(6567):eabj3624. [Content Brief]
[2]. Magg T, et al. Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency. Sci Immunol. 2021 Jun 18;6(60):. [Content Brief]
[3]. Huai W, et al. OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunity. Immunity. 2025 Apr 8;58(4):797-810.e6. [Content Brief]